-transparent.png){kind=logo}
Synthetic thioglycoside-analogs of gangliosides such as Neu5Ac alpha(2-S-6)Glc beta(1-1)Ceramide (1) and the GM3 analog Neu5Ac alpha(2-S-6)Gal beta(1-4)Glc beta(1-1)Ceramide (2), competitively inhibited GM3 hydrolysis by the sialidase of different subtypes of human and animal influenza viruses with an apparent Ki value of 2.8 x 10(-6) and 1.5 x 10(-5) M, respectively. The inhibitory activity of the ganglioside GM4 analog [Neu5Ac alpha(2-S-6)Gal beta(1-1)Ceramide (3)], in which the glucose of 1 was substituted by galactose, was lower than that of 1 (Ki = 1.0 x 10(-4) M). The thioglycoside-analogs (1, 2, 3) of the gangliosides were non-hydrolyzable substrates for influenza virus sialidase. The inhibitory activity of 1 to bacterial sialidases from Clostridium perfringens and Arthrobacter ureafaciens was considerably lower than that to influenza virus sialidase, indicating that the structure of the active site in bacterial and influenza virus sialidase may be different and the analogs may be useful to determine the orientation of the substrate to the active site of sialidases, especially of influenza viruses.
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
May 2006,
Seikagaku. The Journal of Japanese Biochemical Society,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
July 1982,
No to shinkei = Brain and nerve,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
October 1979,
Biochemical and biophysical research communications,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
March 1989,
Human cell,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
May 1990,
Chemical & pharmaceutical bulletin,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
September 1967,
Acta virologica,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
April 1994,
Biochemistry and molecular biology international,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
January 1999,
Progress in medicinal chemistry,
Y Suzuki, and
K Sato, and
M Kiso, and
A Hasegawa
December 1964,
Annals of the New York Academy of Sciences,
